Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2002

View Archived Issues

Banyu researchers identify novel nociceptin ORL1 antagonists

Novel series of CRF1 antagonists prepared and tested at Eisai

Neprilysin inhibitors with utility in female arousal disorder claimed by Pfizer

Ajinomoto patent covers new inhibitors of TNF-alpha production and their use

Antidiabetic pyrazolyl glycosides in Ajinomoto development pipeline

Phase Ib/II trial of Hemospan cleared to begin in Sweden

GPI-1485 selected for evaluation in NINDS-funded Parkinson's program

Zevalin and high-dose BEAM chemotherapy in non-Hodgkin's lymphoma

Oral heparin compared to s.c. LMWH for antithrombotic efficacy after total hip replacement

AAV-mediated FIX gene therapy for hemophilia B discussed at ASH meeting

Modified dosing schedule of apolizumab allows higher doses in CLL and ALL

Nippon Shinyaku acquires rights to Trisenox in certain Asian countries

Dalbavancin enters two phase III trials for the treatment of SSTIs

Completion of phase III Riquent trial announced

Lilly's E.U. submission for ruboxistaurin delayed by phase III trial results

Keryx plans pre-IND meeting with FDA for KRX-123

Approvable letter for Advair Diskus

Fox Chase collaborates with Telik to evaluate anticancer compounds

Lantus: E.U. approval for flexible use, positive opinion for pediatric use

Calsed launched for NSCLC and SCLC

Fujisawa launches Funguard in Japan

Dainippon and Kyorin sign preliminary development agreement for AS-3201

Vertex presents novel p38 kinase inhibitors with broad range of applications

New colchicine-like antiangiogenic agents and their use in cancer and other disorders

RO-14: a new LMWH with a comparable PK/PD profile to fondaparinux in primates

HER-2 DNA AutoVac therapeutic vaccine safe and immunogenic in breast cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...